CAI CORP (00080) net asset value per share at the end of August was approximately HK$0.16.
CAI Corp (00080) announced that as of August 31, 2026, the unaudited net asset value per share of CAI Corp (the Company) and its subsidiaries was approximately HK$0.16.
CAI CORP (00080) announced that as of August 31, 2026, the unaudited net asset value per share of CAI CORP (the Company) and its subsidiaries was approximately HK$0.16.
Related Articles
Zhejiang Wecome Pharmaceutical (300878.SZ): Huangjia Ruangan Granules Approved to Initiate Phase III Clinical Trial for Liver Fibrosis in Chronic Hepatitis B
Jefferies: S&P 500 Index expected to target 8,000 by end-2026, with a potential rise to 9,000 by end-2027.
Beijing Dabeinong Technology Group (002385.SZ) controlling subsidiary's soybean product approved for planting in Brazil
Zhejiang Wecome Pharmaceutical (300878.SZ): Huangjia Ruangan Granules Approved to Initiate Phase III Clinical Trial for Liver Fibrosis in Chronic Hepatitis B
Jefferies: S&P 500 Index expected to target 8,000 by end-2026, with a potential rise to 9,000 by end-2027.
Beijing Dabeinong Technology Group (002385.SZ) controlling subsidiary's soybean product approved for planting in Brazil
RECOMMEND
